BGPartner advises Novo Holdings and LifeArc Ventures in USD 130 million Series B financing of GlycoEra Ltd
28. May 2025
GlycoEra Ltd, a Swiss biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, today announced the closing of a USD 130 million Series B financing. The oversubscribed round was led by Novo Holdings, along with participation from additional new investors LifeArc Ventures, Catalio Capital Management, QIA, MP Healthcare Venture Management, Sixty Degree Capital and Agent Capital. Existing investors, including Sofinnova Partners, 5AM Ventures, Roche Ventures, and Bristol Myers Squibb, also participated.
Max Klement (Partner of Novo Holdings), Matthew Hobson (Principal of Catalio Capital Management) and Sohaib Mir (Partner at LifeArc Ventures) will join as members of the board of directors of GlycoEra.
BGPartner advised the lead investor Novo Holdings and new investor LifeArc Ventures on all Swiss legal matters and the negotiations of this Series B financing round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate), Tessa Douma (Associate) and Anja Spahni (Associate).
More information about our legal and negotiation expertise can be found here.